🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Prognostic information about how long they will be able to #function well is important to more #cancerpatients than a prognosis regarding their #survival, say Japanese researchers. Patients want to plan how they complete unfinished business they suggest. cancerworld.net/knowing-functi…

Shom Goel raises the "🐘 in the room" question, despite being small phase II trials...does the difference between PACE and MAINTAIN suggest we need CDK switching for benefit of CDK after CDK ❓❓ Bigger studies coming! #SABCS22 OncoAlert

High-intensity exercise v low activity can cut #incidence of highly #metastatic #cancers by 73% (P<0.05). Fascinating research indicates metabolic reprogramming induced by exercise enables healthy organs to outcompete cancer cells for nutrients cancerworld.net/aerobic-activi…

#GI23 Zolbetuximab + FOLFOX is a new standard for 1L Claudin18.2+/HER2- adv Gastric/GEJx adenoCA. Some increased GI toxicity. ⁦Dr. Cathy Eng⁩ ⁦Pashtoon Kasi MD, MS⁩ ⁦Sharlene Gill, MD, MPH, MBA, FASCO⁩ ⁦Flavio G Rocha, MD, FACS, FSSO⁩ ⁦@DucreuxMichel⁩ ⁦@FlorianLordick⁩

🔥PRIME II P3 RCT >=65 w/ IDC (T1-2 {<3 cm}, N0, >1 mm margin, HR+ BCS + ET ➡️ +/- RT (40-50 Gy) ⬆️ 10-yr LR: 10% v 1% ‼️ 10-yr LR in ER+ low: 19% v 0% ⬇️ 10-yr DFS: 69% v 76% RT still has value 💪🏾 Impt to fully discuss results in light of 5 fxn RT #radonc #bcsm OncoAlert

🔥Pembrolizumab + CTx as 1st line therapy for HER2-gastric/GEJ cancer 🔥ESMO VIRTUAL PLENARY esmo.org/meeting-calend… ✅KEYNOTE-859 Phase III, 1579 pts 👉ORR 42 vs 51%, 👉mPFS 5.6 vs 6.9mo, 👉mOS 11.5 vs 12.9 mo 🧐Confirmative, PD-L1 appears to be relevant ESMO - Eur. Oncology @oncoalert

FOLFOXIRI plus bevacizumab as standard of care for first-line treatmen... sciencedirect.com/science/articl…

CONTACT3 cabozantinib +/- atezo in VEGF/PD1 pretreated renal cancer did not hit PFS. This torpedoes the theory that switching IO is effective past IO progression. It questions rechallenge of IO after adjuvant pembro. It appears pts get 1 good go at IO businesswire.com/news/home/2023…

Despite continued overall declines, #ColorectalCancer is rapidly shifting to diagnosis at a younger age, at a more advanced stage, and in the left colon/rectum. Read the latest American Cancer Society report: bit.ly/2023CRCStats #ColorectalCancerAwarenessMonth

Now out in The Lancet a patient-level meta-analysis of 100,000 pts from 86 studies led by #EBCTCG ➡️anthracycline + taxane regimens are the most effective in ⬇️relapse risk in #breastcancer Must we challenge the current trend of anthracycline-free CT⁉️ thelancet.com/pdfs/journals/…

Also in 3rd line metastatic colorectal cancer antiangiogenics could play a role OncoAlert

I have tweeted more than 500 times about current information in oncology. My tweet below was the most retweeted tweet in the scientific community. The topic of the tweet is the success of topical diclofenac in reducing HFS. I hope the pharmaceutical industry gets the message.

We know that #ComprehensiveMolecularGenotyping is essential in patients with advanced #NSCLC - but do we know if availability of results impacts #Survival? In a real world cohort study, we asked this question Melina Marmarelis - out now in JCO Precision Oncology ASCO 👉🏽tinyurl.com/2mnbnsxw

🎙️ docetaxel should not be used for high-risk localized #prostatecancer❗️OncoAlert European Urology 📌Ph III RTOG 0521 trial w/ 612 👥; HR localized #prostatecancer randomize to ADT + EBRT✖️ADT + EBRT + docetaxel 🥇🎯:OS 📊RESULTs 👉10-y OS : 64% ADT + EBRT✖️69% ADT + EBRT +

Join us at the next #ESMOVirtualPlenary for the latest ph. 3 trial in #earlyBreastCancer (NATALEE) & learn more on the impact of adjuvant ribociclib on health-related QoL in pts w/ HR+/HER2− #eBC. 🌍 Open to everyone 🔗ow.ly/LsFa50PFtvZ #BCSM Sara Tolaney Michail ignatiadis AACR

In this new study, the authors compared the incidence of infusion-related reactions in patients treated without H2RA to patients receiving standard H2RA premedication. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert CC: Vivek Subbiah, MD

🔥PLENARY Session #ASCO24🔥 Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus 🔎 ESOPEC phase III trial, 438 patients 👉R0 180 vs 171 👉pCR 17 vs 10% 👉mOS 66 vs 37 mo 👉3yr OS: 57.4 vs 50.7% 🧐FLOT improves

Retrospective study of T-DXd rechallenge after ILD: 👉44 pts rechallenged after G1 ILD, 19 after G2 ILD 👉pts received T-DXd for up to 215 more days after ILD 👉ILD recurrence in 16-27% 👉NO G5 We (and patients) need companies to support PROSPECTIVE rechallenge efforts after ILD

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment. #ASCO25

Shocking data 🤯🤯🤯